OCA
KURA icon

Octagon Capital Advisors’s Kura Oncology KURA Stock Holding History

Octagon Capital Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-150,000
Closed -$4.9M – 35
2020
Q4 		$4.9M Buy
+150,000
New +$5.27M 1.7% 20

Other funds holding KURA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Octagon Capital Advisors's KURA Position: Q1 2021 in Review

Octagon Capital Advisors sold out of Kura Oncology (KURA) in Q1 2021, closing a stake of 150,000 shares — an estimated $4.9M sold.

Octagon Capital Advisors first reported a position in KURA in Q4 2020 and held it in 1 quarter. The position peaked at $4.9M in Q4 2020. 171 funds tracked by Wall St. Rank hold KURA as of Q1 2021.

  • Octagon Capital Advisors reported no remaining Kura Oncology position as of Q1 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 150,000 Kura Oncology shares in Q1 2021, an estimated $4.9M.
  • Octagon Capital Advisors first reported a position in Kura Oncology in Q4 2020 and held it in 1 quarter.
  • Octagon Capital Advisors's Kura Oncology position peaked at $4.9M in Q4 2020.
  • 171 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2021.

Based on Octagon Capital Advisors's 13F filing for Q1 2021, filed 17 May 2021.